Supporting first-class drug hunters
Viva Ventures Biotech Fund
We are a VC fund focuses on investments in global first-in-class biotech with significant growth potential, holding periods 70% upto 5 years on average, 30% long period time, the founders having 20+ years drug discovery track record. Our team members included drug hunters, BD experts, ex-investment bankers and seasoned scientists. Viva Ventures is one of very few biotech VCs that have extensive expertise and industry know-how among CVCs.
Started from 1996 for ecosystem building and 1st investment in 2008, Viva Venture Fund I has invested in 9+1* startups with total $23.4 million invested capital out of $25.9 million committed capital. Viva Venture Fund I has generated 5.69X return in 5 years and Fund II has generated 2.3X in value gain in 1 year with 5X over company milestone valuation.
Supporting Biotech Startups since 2008
Viva Ventures Biotech Fund is backed by the founders of top biotech startups and chief scientists of incubator centers, giving us access to the top startups around the world including Viva Biotech incubators, Boston CIC, and Hong Kong Science Park. We also work closely with the top service partners including LLH, PwC, Cooley, Gunderson, CICC and JP Morgan.
Our Clients
On August 26, 2021, the Hong Kong Innovation and Technology Commission announced that the Innovation and Technology Venture Fund (ITVF) has added Viva Ventures Biotech, LP. as one of the co-investment partners (CPs). We are also fortunate enough to serve the SoftBank Asia Co-Founder Andrew Y. Yan as one of the LPs as well as founders of financial institutions, professional experts, family office, entrepreneurs and high-net wealth individuals.
Click to read: Innovation and Technology Venture Fund adds two co-investment partners
Our Strategies
Our Investment Thesis:
Early Stage = Achieve Superior Return
How to Achieve Higher Success Rate:
Genetic Linkage, Biomarkers and SBDD
Phase 2a/2 Clinical Success Rates
Impact of Structure-Based Drug Design (SBDD)
*Source: Nature Review, Volume 13, June 2014
-
Projects that showed greater confidence in target validation through human genetic target linkage to the disease were less likely to fail owing to a lack of efficacy
-
73% of projects with some genetic linkage of the target to the disease were active or successful in Phase II compared with 43% of projects without such data, also that of projects with biomarkers could exceed 80%
Deal Flow Funnel：To Select Top 2% Deals
Past Performance
Exit Record: $3B sale size, 10x return on cash cost in 10 exits, on average holding 3.7Y
Fund I Performance
Fund II Performance
Our Team
Fund Management
Dr. Dai, PhD
Managing Partner
Dr. Mao, PhD
Managing Director
Dr. Cai
Executive Director
Ms. Duan
Legal Director
Dr. Lin, PhD
Research and Business
Development Scientist
Dr. Wang, PhD
Vice President
Ms. Su
Operation Director
Winners Select Winners ：Peer review platform formed by winning Venture Partners, EIR, Advisory Partners, Founders
Who are they
-
Top tier scientists in drug discovery and development
-
Proven successful track record from bench, IND to FDA approval
-
Senior medical R&D management expert in clinical stage
-
Senior experts in deal sourcing and verification
Founders of innovative Biotech
Their track record
Contact Us
Send us a business plan
If you have a great early-stage biotechnological or pharmaceutical project align with our investment strategy, please send your business plan to info@vivaventuresbiotech.com. We look forward to it!